600 related articles for article (PubMed ID: 27137215)
1. Identification of key regulators of pancreatic cancer progression through multidimensional systems-level analysis.
Rajamani D; Bhasin MK
Genome Med; 2016 May; 8(1):38. PubMed ID: 27137215
[TBL] [Abstract][Full Text] [Related]
2. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
3. Weighted gene co-expression network analysis reveals key genes involved in pancreatic ductal adenocarcinoma development.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2016 Aug; 39(4):379-88. PubMed ID: 27240826
[TBL] [Abstract][Full Text] [Related]
4. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
[TBL] [Abstract][Full Text] [Related]
5. Potential four‑miRNA signature associated with T stage and prognosis of patients with pancreatic ductal adenocarcinoma identified by co‑expression analysis.
You L; Wang J; Zhang F; Zhang J; Tao H; Zheng X; Hu Y
Mol Med Rep; 2019 Jan; 19(1):441-451. PubMed ID: 30483731
[TBL] [Abstract][Full Text] [Related]
6. Integrated analysis of mRNA and miRNA expression profiles in pancreatic ductal adenocarcinoma.
Sun H; Zhao L; Pan K; Zhang Z; Zhou M; Cao G
Oncol Rep; 2017 May; 37(5):2779-2786. PubMed ID: 28339085
[TBL] [Abstract][Full Text] [Related]
7. A Network-Based Approach for Identification of Subtype-Specific Master Regulators in Pancreatic Ductal Adenocarcinoma.
Zhang Y; Zhu L; Wang X
Genes (Basel); 2020 Feb; 11(2):. PubMed ID: 32024063
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Topoisomerase 2-Alpha Confers a Poor Prognosis in Pancreatic Adenocarcinoma Identified by Co-Expression Analysis.
Zhou Z; Liu S; Zhang M; Zhou R; Liu J; Chang Y; Zhao Q
Dig Dis Sci; 2017 Oct; 62(10):2790-2800. PubMed ID: 28815403
[TBL] [Abstract][Full Text] [Related]
9. SCNrank: spectral clustering for network-based ranking to reveal potential drug targets and its application in pancreatic ductal adenocarcinoma.
Liu E; Zhang ZZ; Cheng X; Liu X; Cheng L
BMC Med Genomics; 2020 Apr; 13(Suppl 5):50. PubMed ID: 32241274
[TBL] [Abstract][Full Text] [Related]
10. Combined Analysis of the Aberrant Epigenetic Alteration of Pancreatic Ductal Adenocarcinoma.
Xu R; Xu Q; Huang G; Yin X; Zhu J; Peng Y; Song J
Biomed Res Int; 2019; 2019():9379864. PubMed ID: 31956659
[TBL] [Abstract][Full Text] [Related]
11. LncRNA co-expression network analysis reveals novel biomarkers for pancreatic cancer.
Giulietti M; Righetti A; Principato G; Piva F
Carcinogenesis; 2018 Jul; 39(8):1016-1025. PubMed ID: 29796634
[TBL] [Abstract][Full Text] [Related]
12. Construction and analysis of dysregulated lncRNA-associated ceRNA network identified novel lncRNA biomarkers for early diagnosis of human pancreatic cancer.
Zhou M; Diao Z; Yue X; Chen Y; Zhao H; Cheng L; Sun J
Oncotarget; 2016 Aug; 7(35):56383-56394. PubMed ID: 27487139
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA in pancreatic cancer.
Yonemori K; Kurahara H; Maemura K; Natsugoe S
J Hum Genet; 2017 Jan; 62(1):33-40. PubMed ID: 27251005
[TBL] [Abstract][Full Text] [Related]
14. Comparison of tumour and serum specific microRNA changes dissecting their role in pancreatic ductal adenocarcinoma: a meta-analysis.
Chhatriya B; Mukherjee M; Ray S; Sarkar P; Chatterjee S; Nath D; Das K; Goswami S
BMC Cancer; 2019 Dec; 19(1):1175. PubMed ID: 31795960
[TBL] [Abstract][Full Text] [Related]
15. Integrated microRNA-mRNA analysis of pancreatic ductal adenocarcinoma.
Liu PF; Jiang WH; Han YT; He LF; Zhang HL; Ren H
Genet Mol Res; 2015 Aug; 14(3):10288-97. PubMed ID: 26345967
[TBL] [Abstract][Full Text] [Related]
16. MicroRNAs cooperatively inhibit a network of tumor suppressor genes to promote pancreatic tumor growth and progression.
Frampton AE; Castellano L; Colombo T; Giovannetti E; Krell J; Jacob J; Pellegrino L; Roca-Alonso L; Funel N; Gall TM; De Giorgio A; Pinho FG; Fulci V; Britton DJ; Ahmad R; Habib NA; Coombes RC; Harding V; Knösel T; Stebbing J; Jiao LR
Gastroenterology; 2014 Jan; 146(1):268-77.e18. PubMed ID: 24120476
[TBL] [Abstract][Full Text] [Related]
17. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA modulated networks of adaptive and innate immune response in pancreatic ductal adenocarcinoma.
Felix TF; Lopez Lapa RM; de Carvalho M; Bertoni N; Tokar T; Oliveira RA; M Rodrigues MA; Hasimoto CN; Oliveira WK; Pelafsky L; Spadella CT; Llanos JC; F Silva G; Lam WL; Rogatto SR; Amorim LS; Drigo SA; Carvalho RF; Reis PP
PLoS One; 2019; 14(5):e0217421. PubMed ID: 31150430
[TBL] [Abstract][Full Text] [Related]
19. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
20. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
